Financhill
Back

Summit Therapeutics Quote, Financials, Valuation and Earnings

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!
Buy
70

SMMT
Summit Therapeutics

Last Price:
20.75
Seasonality Move:
32.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Summit Therapeutics Price Quote

$20.75
-1.04 (-4.77%)
(Updated: November 12, 2024 at 5:20 PM ET)

Summit Therapeutics Key Stats

Buy
70
Summit Therapeutics (SMMT) is a Buy

Day range:
$21.42 - $22.53
52-week range:
$1.79 - $33.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
16,170.58
P/B ratio:
36.69%

Volume:
2.1M
Avg. volume:
2.8M
1-year change:
1043.83%
Market cap:
$16.1B
Revenue:
$0
EPS:
$-0.24

How Much Does Summit Therapeutics Make?

Data Unavailable

Is Summit Therapeutics Growing As A Company?

Data Unavailable

Summit Therapeutics Stock Price Performance

What Is Summit Therapeutics 52-Week High & Low?

Summit Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Summit Therapeutics?

Is Summit Therapeutics Cash Flow Positive?

  • What Is SMMT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$112.9M
  • What Is Summit Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $411.1M
  • What Is Summit Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$228.3M

Summit Therapeutics Return On Invested Capital

Data Unavailable

Summit Therapeutics Earnings Date & Stock Price

Summit Therapeutics Competitors

Summit Therapeutics Dividend Yield

Summit Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -19.41%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 34.70
Upside from Last Price: 59.25%

Major Shareholders

  • How many SMMT shares are owned by institutional investors?
    102.3M SMMT shares are owned by institutional investors
  • How many SMMT shares are owned by insiders?
    142.7M SMMT shares are owned by insiders